The concept of using radiolabelled antibodies to deliver radiation specifically to cells expressing specific antigens has a longstanding history in preclinical nuclear medicine research [1] [2] [3] . Several approaches were used as long ago as some 50 years to evaluate the potential therapeutic effect in different xenograft models [2, 3] . Promising results were shown in different tumour cell lines in vitro and in vivo [4] [5] [6] [7] . One of the first human applications was reported in the late 1960s [8] . All these studies have in common that they used heterologous antibodies generated in different species and mostly labelled with 131 I. Due to the large size of complete antibodies they display a less favourable biodistribution pattern. One of the important aspects is a rather long blood-pool half-life which leads to an increased risk of deiodination and thereby the risk of an increased dose to the thyroid and at the same time lower accumulation in the targeted tumour. Other radionuclides such as 90 Y [9] , 177 Lu [10] or different alpha-emitters (see for example Chen et al. [11] ) might be more effective due to a expected higher linear energy transfer and a higher stability in vivo. Furthermore, complete antibodies are more easily recognized by FcR-expressing cells such as macrophages and granulocytes. Another point is the expected diminished capacity for penetration into tumours due to the size of the antibodies.
In haematooncological malignancies, two monoclonal antibodies against the surface antigen CD20, overexpressed in B-cell lymphomas, have made their way into registration and thereby clinical application outside study protocols [12] . In solid tumours several phase I and II studies have been performed, but a registered product is not yet available (see for example Stillebroer et al. [10] ).
It is intriguing that as early as almost 30 years ago a study evaluated a promising approach in refractory Hodgkin lymphoma using a 131 I-labelled antiferritin antibody showing a symptomatic response rate of almost 80 % [13] . Several studies followed with the same polyclonal antibody, some of them using 90 Y as the radionuclide, with comparable results [14] . Despite these seemingly good results only a few further studies followed, the last one in 2007 in ten patients [15] . In a phase I study another approach, a chimeric antibody to the alpha chain of the interleukin-2 receptor (CD25), was evaluated with promising results [16] , but no further studies have been published. One of the problems of the concepts was most likely the nonhumanized antibodies and/or the use of a polyclonal antibody. But in the author's opinion, the broad underlying problem -not only concerning new radiolabelled therapeutic agents but in general a lot of promising new molecular probes for theranostic applications -lies most likely in the lack of economic power behind these concepts. Within academia phase 0 and I, and perhaps even phase II, studies can be financed, but at the point of registration and potential translation to general clinical application big pharma companies should come into the field, and that in a lot of cases is simply not happening. The current options for European grants within the new Horizon 2020 programme [17] might give the opportunity to establish consortia for the realization of larger multicentre trials.
Regarding the biodistribution of the complete antibodies so far evaluated in most studies, developments in the engineering of antibodies and antibody fragments might provide a completely new opportunity for theranostic concepts using specific extracellular or cellular surface targets in personalized medicine and could potentially further accelerate the concept of delivering radioactivity directly to the target [18] . The potential role played by nanotheranostics in this context should also be mentioned.
In the current issue of the European Journal of Nuclear Medicine and Molecular Imaging, Luigi et al. [19] present the results of a phase I/II study in eight patients with therapyrefractory Hodgkin lymphoma using a radiolabelled miniantibody against the extracellular matrix (ECM) domain molecule tenascin-C (TC-A1). In a previous study other tumour entities were also treated with a comparable radiopharmaceutical [20] . Tenascin-C plays a role in the mechanical and signalling function of the ECM in inflammatory processes (especially chronic inflammation) as well as in cancerogenesis and is therefore a potentially interesting target for a variety of malignancies [21] . Moreover, tenascin-C is involved in angioneogenesis and its expression has been shown to correlate with the degree of vascularization of the tumour. Especially in malignant lymphoma, tenascin-C expression is correlated with a poor prognosis [21] . These features support the statement that the new miniantibody TC-A1 (Tenarad) has the potential to become an important radioimmunopharmaceutical in several tumour entities either as a first-line therapy or in combination with standard chemotherapies. In general radioimmunoimaging and radioimmunotherapy, together radioimmunotheranostics, are siblings with a bright future if enough economic and scientific power is made available for their further evolution.
